Figure 2. Mutant neoantigen–specific peptide vaccines induce therapeutic effects comparable to those of checkpoint blockade therapy.

Kaplan-Meier survival curves of tumor-bearing mice therapeutically vaccinated with a vaccine comprising poly I:C plus either ALG8 plus LAMA4 SLP, control SLP (HPV peptide), or buffer (A) or therapeutically treated with mAbs to CTLA-4 and/or PD-1 immune checkpoints (B). Adapted with permission from Nature (ref. 77; Figure 1A and Figure 2, D and E)